At a glance
ClinicalIndex Comparison RecordN/ACompleted· 45 enrolled
Drug / intervention
GRIP Electronic Diagnostic Chip +1 moredevice
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Clinical Evaluation of the GRIP Influenza and SARS-CoV-2 Point-of-care Assays Using Fresh Patient Nasal Swab Samples
In Brief
A clinical study evaluating GRIP Electronic Diagnostic Chip and Laboratory-based nucleic acid amplification tests (NAATs) for COVID-19 and Influenza. Completed, enrolled 45 participants across 1 site.
Detailed Summary
The purpose of this research is to determine if the use of a new device can accurately detect a virus infection.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesUnited States
CollaboratorsDepartment of Health and Human Services
Timeline
N/ACompletedFinished
2023202420252026
First PostedJan 2023
Enrollment StartFeb 2023
Primary CompletionApr 2023
TodayJul 2026
First PostedJan 6, 2023
Enrollment StartFeb 1, 2023
Primary CompletionApr 30, 2023
TodayJul 2, 2026
Enrollment to primary: 3 monthsPosted 3.5 years ago
Interventions
GRIP Electronic Diagnostic Chipdevice
Graphene-based point-of-care device for detection of respiratory viruses (e.g., COVID-19 and influenza) from a nasal swab
Laboratory-based nucleic acid amplification tests (NAATs)other
Polymerase Chain Reaction (PCR) analysis for detection of viruses (e.g., Roche cobas SARS-CoV-2 or influenza A/B) from nasal swab